The Dutch biotech company Qiagen has increased its total sales in the third quarter of 2012 at constant exchange rates by ten percent to $304.3 million (EUR 238 million). Double-digit growth was registered in the U.S. and Asia, the company with its headquarters in Hilden reported.
Adjusted net income increased by 11 percent to 62 million dollars (49 million euros) in the reporting period compared to last year.
In the first nine months of 2012, Group sales at constant exchange rates recorded double-digit growth (+12%), driven by a steady growth in all customer groups – especially molecular diagnostics and applied testing procedures – and in all regions.
The acquisition of Cellestis, Ipsogen and AmniSure controlled at constant exchange rates accounted for seven percentage points of growth, while five percent accounted for the remaining Qiagen portfolio.
[ilink url=“http://www.qiagen.com/about/pressreleases/pressreleaseview.aspx?PressReleaseID=396&lang=DE“] Link zur Quelle (Qiagen)[/ilink]